%---

FDG-PET/CT has is a great addition to the diagnostic approach for pancreatic cancer by combining anatomical and metabolic imaging. It has the ability to localize tumors, stage disease, and guide therapy making it a solid choice for oncology assessment. However, addressing its limitations through advanced tracers and hybrid modalities is a priority. The ongoing evolution of PET/CT technology, coupled with global efforts to expand accessibility, will undoubtedly enhance its impact on pancreatic cancer outcomes.
